EPHA2 and prostate carcinoma: The phage display method was used to discover the agonistic peptide SWL, which was demonstrated to activate EphA2 phosphorylation, and blocked major oncogenic pathways such as via Erk MAP kinases and Akt in PC3 prostate cancer cells, consistent with EphA2-mediated tumour suppression.